It is likely that the effectiveness of immunotherapy in KRASmut NSCLC patients does not depend only on the presence of druggable lesions in this gene, but also on the molecular background—co-mutations in the STK11, KEAP1 and TP53 genes. Here, TP53 is linked to non-small cell lung carcinoma.